The aim of this study was to investigate whether or not
peiminine inhibits
lung inflammation and
pulmonary fibrosis in a rat model of
bleomycin-induced
lung injury. Rats were randomly divided into 4 groups. In 3 groups, intratracheal
bleomycin (5 mg/kg) was used to induce
acute lung injury, followed by administration of either
carboxymethyl cellulose (control group, n=14),
dexamethasone (DXS group, n=14) or
peiminine (
peiminine group, n=10). In the fourth group (
sham-operated, n=12),
normal saline was instilled instead of
bleomycin, followed by administration of
carboxymethyl cellulose. Drugs were administered intragastrically for 28 days. Lung sections were stained with
hematoxylin and
eosin (H&E) and Masson's trichrome, to grade the degree of alveolitis and
pulmonary fibrosis. The lung index was calculated as the ratio of lung to
body weight. Serum levels of
interleukin-4 (IL-4),
tumor necrosis factor-α (TNF-α) and
interferon-γ (IFN-γ) were obtained using a radioimmunoassay. Immunocytochemical methods were employed to assess the expression of
transforming growth factor-β (TGF-β),
connective tissue growth factor (CTGF), NF-κB, extracellular signal-related
kinase (ERK1/2), Fas and FasL in lung tissue.
Peiminine and DXS significantly reduced alveolar
inflammation and pulmonary interstitial
inflammation in rats with
bleomycin-induced
lung injury. These protective effects were associated with significant (P<0.05) decreases in the levels of IFN-γ in serum and of TGF-β, CTGF, ERK1/2, NF-κB and FasL in lung tissue. No effects were observed on serum TNF-α or
IL-4. In conclusion,
peiminine inhibits
lung inflammation and
pulmonary fibrosis in a rat model of
bleomycin-induced
lung injury, by reducing circulating IFN-γ levels and inhibiting signal transduction pathways involving TGF-β, CTGF, ERK1/2, NF-κB and FasL.